PDL BioPharma (PDLI) Reports Mixed Q3 Results; Narrows FY09 Sales Guidance
More News related to PDLI
- PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
- PDL BioPharma (PDLI) Approves Special Dividend
- PDL BioPharma Announces Special Dividend Payment
- PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
PDL BioPharma, Inc. (Nasdaq: PDLI) reports Q3 EPS of $0.29, 3 cents better than the analyst estimate of $0.26. Revenue for the quarter was $71.45 million, which compares to the estimate of $76.48 million.
Narrows its FY09 sales guidance from $310-$325 million to $310-$320 million, versus the consensus of $331.96 million.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
